Epigral Limited — Updates, 05-05-2025: Press Release

Epigral reported Q4 PAT at ₹87 Cr, up 13%, on 20% higher revenue of ₹631 Cr, led by volume growth in Derivatives & Specialty, now contributing 52% of sales. FY2025 revenue rose 33% to ₹2,565 Cr with PAT surging 82% to ₹357 Cr and EBITDA margin expanding to 28%. Net Debt/EBITDA improved to 0.7x, supporting a Crisil AA upgrade. The company greenlit ₹195 Cr capex to expand CPVC Resin (1.5 LTPA) and Epichlorohydrin (1 LTPA) capacities, aiming for FY2027 commissioning to drive specialty chemical segment growth.